Rep. Lisa C. McClain Purchases Shares of Novartis AG (NYSE:NVS)

Representative Lisa C. McClain (R-Michigan) recently bought shares of Novartis AG (NYSE:NVS). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in Novartis stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Novartis Stock Performance

Shares of NVS stock opened at $130.28 on Wednesday. The company has a market capitalization of $275.20 billion, a price-to-earnings ratio of 17.80, a price-to-earnings-growth ratio of 1.93 and a beta of 0.60. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.62 and a current ratio of 0.88. Novartis AG has a one year low of $96.06 and a one year high of $134.00. The company’s 50-day moving average is $127.84 and its 200 day moving average is $122.25.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.26 by ($0.01). The firm had revenue of $14.36 billion during the quarter, compared to analysts’ expectations of $13.70 billion. Novartis had a return on equity of 41.21% and a net margin of 26.49%.The firm’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the firm posted $2.06 earnings per share. Sell-side analysts expect that Novartis AG will post 8.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on NVS shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a report on Thursday, August 21st. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a report on Thursday, November 20th. HC Wainwright cut Novartis to a “neutral” rating in a research note on Monday, October 27th. Morgan Stanley raised Novartis from an “equal weight” rating to an “overweight” rating in a report on Friday, October 31st. Finally, Wall Street Zen downgraded Novartis from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $122.33.

Institutional Trading of Novartis

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its position in Novartis by 60.3% in the first quarter. Goldman Sachs Group Inc. now owns 3,660,485 shares of the company’s stock worth $408,071,000 after purchasing an additional 1,377,252 shares during the last quarter. New Vernon Capital Holdings II LLC lifted its stake in shares of Novartis by 12,664.1% in the 1st quarter. New Vernon Capital Holdings II LLC now owns 1,383,244 shares of the company’s stock worth $154,204,000 after purchasing an additional 1,372,407 shares during the period. Raymond James Financial Inc. boosted its holdings in shares of Novartis by 77.7% in the third quarter. Raymond James Financial Inc. now owns 1,648,174 shares of the company’s stock worth $211,362,000 after buying an additional 720,860 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in Novartis during the third quarter valued at approximately $64,563,000. Finally, Bank of Montreal Can increased its holdings in Novartis by 85.0% during the third quarter. Bank of Montreal Can now owns 1,045,191 shares of the company’s stock valued at $134,035,000 after buying an additional 480,201 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.